NanoViricides (NNVC) vs Rein Therapeutics (RNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NanoViricides (NNVC) has outperformed Rein Therapeutics (RNTX) over the past year, losing 10.2% versus a loss of 77.2%. Over five years, NNVC leads with a -76.5% price change compared with -97.5% for RNTX. NanoViricides is the larger company by market cap ($29.1 million vs $29.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNVC | RNTX |
|---|---|---|
| Share price | $1.14 | $0.3369 |
| Market cap | $29.13M | $29.06M |
| 1-day change | -2.56% | -8.38% |
| YTD return | +0.88% | -70.96% |
| 1-year return | -10.24% | -77.24% |
| 5-year return | -76.54% | -97.47% |
| EPS (TTM) | $-0.53 | $-1.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $0 |
| Net income (latest FY) | $-8.22M | $-49.87M |
| 52-week high | $1.93 | $2.10 |
| 52-week low | $0.85 | $0.284 |
| Distance from 52-week high | -40.93% | -83.96% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +426.32% | +1680.94% |
| Average volume | 356.86K | 586.68K |
| Shares outstanding | 25.55M | 86.27M |
| Employees | 7 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NNVC has outperformed RNTX by 67.0 percentage points over the past year.
About NanoViricides
NNVC stock →NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
NNVC vs RNTX FAQ
Which is bigger, NanoViricides or Rein Therapeutics?
NanoViricides (NNVC) is larger, with a market capitalization of $29.13M compared with $29.06M for Rein Therapeutics (RNTX).
Which stock has performed better over the past year, NNVC or RNTX?
NNVC returned -10.24% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are NanoViricides and Rein Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.